Literature DB >> 29388202

An overview of cervical cancer epidemiology and prevention in Scandinavia.

Kine Pedersen1, Sara Fogelberg2, Lise H Thamsborg3, Mark Clements2, Mari Nygård4, Ivar S Kristiansen1, Elsebeth Lynge3, Pär Sparén2, Jane J Kim5, Emily A Burger1,5.   

Abstract

New technologies such as human papillomavirus (HPV) testing and vaccination necessitate comprehensive policy analyses to optimize cervical cancer prevention. To inform future Scandinavian-specific policy analyses, we aimed to provide an overview of cervical cancer epidemiology and existing prevention efforts in Denmark, Norway and Sweden. We compiled and summarized data on current prevention strategies, population demography and epidemiology (for example, age-specific HPV prevalence and cervical cancer incidence over time) for each Scandinavian country by reviewing published literature and official guidelines, performing registry-based analyses using primary data and having discussions with experts in each country. In Scandinavia, opportunistic screening occurred as early as the 1950s and by 1996, all countries had implemented nationwide organized cytology-based screening. Prior to implementation of widespread screening and during 1960-66, cervical cancer incidence was considerably higher in Denmark than in Norway and Sweden. Decades of cytology-based screening later (i.e. 2010-2014), cervical cancer incidence has been considerably reduced and has converged across the countries since the 1960s, although it still remains lowest in Sweden. Generally, Scandinavian countries face similar cervical cancer burdens and utilize similar prevention approaches; however, important differences remain. Future policy analyses will need to evaluate whether these differences warrant differential prevention policies or whether efforts can be streamlined across Scandinavia.
© 2018 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  Cervical cancer; Scandinavia; human papillomavirus; mass screening; prevention

Mesh:

Year:  2018        PMID: 29388202     DOI: 10.1111/aogs.13313

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  14 in total

1.  Exploring the adverse effects of chemotherapeutic agents used in the treatment of cervical and ovarian cancer from the patients' perspective: a content analysis of the online discussion forums.

Authors:  Sulaf Assi; Megan Barling; Abdullah Al-Hamid; Ejaz Cheema
Journal:  Eur J Hosp Pharm       Date:  2020-04-29

2.  Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer.

Authors:  Susanne K Kjaer; Christian Dehlendorff; Federica Belmonte; Louise Baandrup
Journal:  J Natl Cancer Inst       Date:  2021-10-01       Impact factor: 13.506

3.  Cervical cancer in women under 30 years of age in Norway: a population-based cohort study.

Authors:  Brit Helene Gravdal; Stefan Lönnberg; Gry Baadstrand Skare; Gerhard Sulo; Tone Bjørge
Journal:  BMC Womens Health       Date:  2021-03-18       Impact factor: 2.809

4.  Impact of Delaying Effective and Cost-Effective Policy Decisions: An Example From Cervical Cancer Prevention in Norway.

Authors:  Allison Portnoy; Mari Nygård; Lill Trogstad; Jane J Kim; Emily A Burger
Journal:  MDM Policy Pract       Date:  2022-01-04

5.  Multimodal MRI Analysis of Cervical Cancer on the Basis of Artificial Intelligence Algorithm.

Authors:  Bin Wang; Yuanyuan Zhang; Chunyan Wu; Fen Wang
Journal:  Contrast Media Mol Imaging       Date:  2021-11-08       Impact factor: 3.161

6.  Evaluation of the efficacy of laparoscopic-assisted radical vaginal hysterectomy and abdominal radical hysterectomy for treating cervical cancer: a meta-analysis.

Authors:  Zhen Zeng; Jia Liu; Tao Lv; Zonghao Feng; Lei Zhang; Qinping Liao
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-05-14       Impact factor: 1.195

7.  Cervical cancer prevention among long-term screening non-attendees by vaginal self-collected samples for hr-HPV mRNA detection.

Authors:  Avalon Ernstson; Annika Urdell; Ola Forslund; Christer Borgfeldt
Journal:  Infect Agent Cancer       Date:  2020-02-13       Impact factor: 2.965

8.  Screening participation after a false positive result in organized cervical cancer screening: a nationwide register-based cohort study.

Authors:  Pernille Thordal Larsen; Susanne Fogh Jørgensen; Mette Tranberg; Sisse Helle Njor
Journal:  Sci Rep       Date:  2020-09-22       Impact factor: 4.379

9.  Study protocol of the ACCESS trial: a randomised trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection.

Authors:  Misuzu Fujita; Minobu Shimazu; Kengo Nagashima; Misae Suzuki; Ichiro Tauchi; Miwa Sakuma; Setsuko Yamamoto; Makio Shozu; Hideki Hanaoka; Nobuhide Tsuruoka; Tokuzo Kasai; Akira Hata
Journal:  BMJ Open       Date:  2022-02-03       Impact factor: 2.692

10.  Identify Function of WASL in Prognosis of Cervical Cancer Based on Omics Data.

Authors:  Jinxuan Hou; Chen Chen; Yingying Hu; Qing Gong; Lijuan Gan; Yu Xu
Journal:  Front Cell Dev Biol       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.